Paid Clinical Trials for Metastatic Malignant Solid Neoplasm

Showing 1 – 20 of 34 results

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

by CTG

in Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain

Other

Arizona

Deadline:

02/15/2028

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

by CTG

in Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Clear Cell Renal Cell Carcinoma, Aggressive Variant Prostate Carcinoma

Other

Texas

Deadline:

12/31/2026

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

by CTG

in Metastatic Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer

Other

California

Deadline:

03/31/2028

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Other

California

Deadline:

09/24/2026

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma

Other

California

Deadline:

03/01/2027

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

Other

Alabama

Deadline:

04/16/2026

Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

by CTG

in Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain

Other

Ohio

Deadline:

06/28/2026

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

by CTG

in Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm

Other

Arizona

Deadline:

03/01/2027

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Lymphoma, Caregiver, Recurrent Leukemia

Other

Texas

Deadline:

12/31/2027

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

by CTG

in Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm

Other

Maryland

Deadline:

10/15/2026

Radiosurgery Before Surgery for the Treatment of Brain Metastases

by CTG

in Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain

Other

Georgia

Deadline:

02/19/2027

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

by CTG

in Recurrent Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8

Other

California

Deadline:

10/01/2026

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

by CTG

in Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm

Other

Minnesota

Deadline:

04/07/2028

Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients

by CTG

in Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm

Other

Minnesota

Deadline:

12/01/2029

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

by CTG

in Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable Solid Neoplasm

Other

Arizona

Deadline:

08/27/2026

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

by CTG

in Stage III Lung Cancer AJCC v8, Metastatic Pancreatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Lung Small Cell Carcinoma

Other

Arizona

Deadline:

03/04/2026

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

by CTG

in Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone

Other

California

Deadline:

01/26/2027

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

by CTG

in Metastatic Malignant Solid Neoplasm, Stage IV Bladder Cancer AJCC v8, Metastatic Bladder Urothelial Carcinoma

Other

Illinois

Deadline:

05/10/2030

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

by CTG

in Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Other

California

Deadline:

11/21/2026

Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial

by CTG

in Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone

Other

Alaska

Deadline:

02/01/2029

Load more All clinical trials loaded.

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Metastatic Malignant Solid Neoplasm

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps